Panos Stergiou, (Thessaloniki, Greece), Kostantinos Malamos, MD (Thessaloniki, Greece), Efstathios Dragiotis, MD (Thessaloniki, Greece), Anastasios Felekidis, MD (Thessaloniki, Greece), Tania Karagiani, MD (Thessaloniki, Greece), Stavros Dimitrakos, MD (Thessaloniki, Greece)


To investigate whether combined intravitreal use of triamcinolone (Kenacort) and bevacizumab (Avastin) can prolong the beneficial effect and reduce the need for monthly injections, for the treatment of choroidal neovascularization (CNV).


We performed a retrospective chart review of medical files of patients diagnosed with age related macular degeneration due to choroidal neovascularization (CNV). 52 eyes of 29 patients received combined intravitreal triamcinolone 0.05ml=2mg plus bevacizumab 0.05ml =1.25mg (total 0,1ml) every second month for the first six months. Ophthalmic evaluations included visual acuity (VA), complete ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography (OCT).


All patients completed at least 6 months of follow-up and were included in the study. Dramatic improvement, mainly in the OCT and the angiographic appearance, was achieved from the first postoperative week. Visual acuity stabilized or improved in all cases.


Ken-Av (Kenacort-Avastin) is a promising potent and long lasting anti VEGF combination for patients with wet type macular degeneration. Bimonthly administration of intravitreal (Ken-Av) Kenacort- Avastin is effective in eliminating the  subretinal fluid, halting the neovascular process and stabilizing or improving visual acuity.